Objective: In many countries, including Canada, a small proportion of people with psychotic disorders receive long-acting injectable (LAI) antipsychotics (APs), despite their demonstrated effectiveness and possible advantages for improving adherence rates. Attitudes regarding LAIs among physicians may influence their prescribing practices and thereby contribute to the underuse of LAIs. Here, we report on a qualitative study of perceptions and attitudes toward LAIs among psychiatrists in Canada.
Clinical Implications
• The predominant use of LAIs as an end-of-the-road option, in a context of either coercion or a fragile therapeutic relationship owing to a history of treatment nonadherence, may continue to reinforce a negative image of LAIs.
• To increase the use of LAIs by physicians, systemic changes may have to be implemented to address pragmatic barriers of high costs, lack of storage facilities, and lack of trained staff to administer injections.
• Physicians may need better education about and increased familiarity with LAIs to improve use of LAIs.
Limitations
• A relatively small sample of psychiatrists participated in the focus groups, limiting the generalizability of the results. However, an attempt was made to include psychiatrists from 4 provinces in Canada.
• Important sociodemographic information (for example, years of experience) was not collected, which limits our ability to draw conclusions about possible influences on psychiatrists' attitudes about LAIs.
T he rates of medication nonadherence are high in schizophrenia and other psychoses, 1-3 with significant negative consequences, such as relapse and rehospitalization. 1 An estimated 40% of the total costs associated with schizophrenia are attributed to rehospitalizations. 4 Using LAI antipsychotics is one of several strategies to enhance medication adherence among patients with psychotic disorders. However, in many regions of the world, and particularly in North America, very few people with psychotic disorders receive LAIs. [5] [6] [7] [8] [9] [10] [11] [12] Attitudes of physicians toward certain types of treatments or treatment modalities may play a crucial role in shaping their prescribing practices, 13, 14 and patients' acceptance of those treatments. 15 Thus attitudes of psychiatrists towards LAIs may contribute to the strikingly low use of LAIs for the treatment of psychotic disorders. Nevertheless, there have been, to our knowledge, only 6 studies (4 in Europe, [16] [17] [18] [19] 1 in Australia, 20 and 1 in New Zealand 21 ) investigating psychiatrists' attitudes toward LAIs and none in Canada. Most of these studies, with one exception, 16 found largely positive attitudes toward LAIs among psychiatrists. Notwithstanding such positive attitudes, most studies also found a gap between attitudes of psychiatrists and their practice, with relatively few patients being prescribed LAIs; a reluctance to prescribe LAIs in the early phases of psychotic disorders; and a continued perception of LAIs as being appropriate only for those seen as poorly adherent. So far, these few studies have predominantly used questionnaire or survey methodology. Much more nuanced information regarding physician attitudes toward LAIs (for example, subjective perceptions of advantages, disadvantages, and barriers to use) may be needed before planning any efforts to bring about more balanced attitudes. Therefore, our study investigated attitudes, beliefs, and perceptions held by psychiatrists regarding LAIs using focus group methodology.
Une étude qualitative des expériences avec les antipsychotiques injectables à action prolongée et des perceptions à ce sujet : 2e partie -Perspectives des médecins
Objectif : Dans de nombreux pays, dont le Canada, seule une petite proportion de personnes souffrant de troubles psychotiques reçoit des antipsychotiques (AP) injectables à action prolongée (IAP), malgré leur efficacité démontrée et leurs avantages possibles d'améliorer les taux d'observance. Les attitudes des médecins à l'égard des IAP peuvent influencer leurs pratiques de prescription et subséquemment contribuer à la sous-utilisation des IAP. Ici, nous faisons le compte rendu d'une étude qualitative des perceptions et des attitudes à l'égard des IAP chez les médecins du Canada.
Méthode : Des groupes de discussion ont été formés de 24 psychiatres dans 4 provinces canadiennes. Les groupes de discussion portaient sur les expériences avec les AP IAP et les attitudes à leur égard. Les séances ont fait l'objet d'un enregistrement sonore et ont été transcrites textuellement, et ces transcriptions ont été codées à l'aide d'une procédure hybride de méthodes déductives et inductives. un questionnaire abrégé a été administré avant le groupe de discussion.
Résultats :
Les questionnaires précédant le groupe de discussion ont indiqué que les psychiatres de notre étude prescrivaient la formule orale des AP la plupart du temps, et qu'ils avaient une expérience limitée des IAP. Les groupes de discussion ont dégagé 4 principaux thèmes : une expérience et des connaissances limitées des IAP; les attitudes à l'égard des IAP (croyances que les patients ont des perceptions négatives à l'égard des IAP, préjugés personnels contre les aiguilles, et consensus à propos de certains avantages des IAP); les pratiques de prescription des IAP (généralement vus comme une option de derniers recours pour les patients ayant des antécédents de non-observance); et les obstacles pratiques (par exemple, coût, entreposage, et dotation en personnel) à l'utilisation des IAP. 
Conclusion

Method
Focus Group Participants
In 2010, 4 focus groups were conducted, 1 each in Halifax, Nova Scotia; Quebec City, Quebec; London, Ontario; and Victoria, British Columbia. Our study was approved by the relevant research ethics committees at each site. Specific attempts were made to recruit psychiatrists who treated patients with psychotic disorders, with the help of 4 coauthors (Dr Roy, Dr Tibbo, Dr Manchanda, and Dr Williams). No information was available about the actual prescribing practices or views of the psychiatrists who were invited to participate. Written informed consent was obtained from each psychiatrist. Psychiatrists were offered an honorarium for their participation. The final sample included 24 psychiatrists: 15 men and 9 women (5 from Halifax, 6 from Quebec City, 6 from London, and 7 from Victoria).
Focus Group Sessions
A focus group interview schedule with broad, open-ended questions regarding attitudes toward and prescribing practices around LAIs was developed. The focus groups lasted for 90 minutes, on average. All sessions were conducted by 2 trained facilitators; interviews were held in French at the Quebec site, and in English at the other locations. Psychiatrists were requested to fill out a brief questionnaire prior to the focus group about their typical practice setting and experience with LAIs. Participants were assured that the funding sponsor of the study had no role in the design of the interview schedule and data analysis.
Analysis
Frequency analysis was done with the pre-focus group questionnaire data. The focus group discussions were audiotaped, with the agreement of participants. The recorded material was fully transcribed. The transcribed data were analyzed by the sorting of verbatim material into themes, guided by the specific questions and topics that were probed for while concurrently allowing the data to suggest themes. Our accompanying paper (see Part I; Chaper 2; Iyer et al 22 ) provides further details about our method of data analysis.
Results
Pre-Focus Group Questionnaires
Eleven (52.4%) psychiatrists reported working primarily in inpatient settings; 6 (28.6%) primarily in outpatient settings; and 5 (24%) in both in-and outpatient settings. Nine psychiatrists further described their setting: 5 reported working in both community and university settings; 1 in only a community setting; 2 in only a university setting; and 1 in only a forensic setting. Physicians indicated that they prescribed the oral formulation of SGAs most of the time ( Figure 1 ) and that they had limited experience with LAIs. A majority (n = 21, 88%) had not personally administered an LAI AP and reported that a nursing staff member administered the injection in their work environment. The level of technical skill required to administer LAIs was perceived to be moderate by 17 psychiatrists (71%), high by 4 (17%), and low or none by 3 (12%). Nearly all psychiatrists in our study reported using LAIs with patients entering treatment both voluntarily and involuntarily. Only Psychiatrists, n 1 psychiatrist (working in a forensic setting) reported using LAIs only with patients entering treatment involuntarily.
Focus Group Results
All of the analyzed data could be organized around 4 main themes: limited knowledge about and experience with LAIs, attitudes towards LAIs, prescribing practices around LAIs, and pragmatic barriers to using LAIs. Each of these categories is described below and illustrative quotations are presented.
Knowledge About and Experience With LAIs
A major theme that emerged was psychiatrists' lack of knowledge about LAIs (for example, available options, side effects, and outcome literature) and lack of confidence in extant knowledge. In this context, participants discussed their limited prior exposure to LAIs and how this possibly contributed to their low use of LAIs. Below are a few quotes illustrative of this theme:
So another thing for me, personally, I haven't given one, for, since I was a resident . . . so I can't remember the last time that I did that, but I do know it was a very long time ago; there's a new injectable now . . . I wouldn't know where to start with it, so I need a bit of a learning curve to understand how to give them, to expect what the side effects were.
I don't know that much about injectables, and I know that the new second-generation Risperdal is the only one I know is there, but maybe there's more that I don't know.
If it's not being practiced by the consultants that you're training under, so then you're unlikely to kind of go that route.
Consistent with the results of the pre-focus group questionnaires, infrequent use of LAIs by most participants emerged as a theme. Pertinent quotations are, "I don't use that often," "I don't think I've initiated an LAI, ever," and "I might be able to count on my hand . . . "
Attitudes Toward LAIs
There were 3 important subthemes under attitudes toward LAIs: beliefs about patient perceptions regarding LAIs; personal bias against LAIs; and advantages and risks of LAIs.
Beliefs About Patient Perceptions Regarding LAIs. Psychiatrists had several beliefs about patients perceiving LAIs negatively, including the following:
1. Patients feel controlled or perceive LAIs as more intrusive or coercive.
I think there's a lot more control, at least it's perceived control, to them [patients], if they're on oral, because they decide whether they want to take it or not, but an injectable they have no option, if they don't take it we slam the CTO on them and they will have to take it, so there is no control.
. . . unlike a pill they can manage themselves, with the injection they need somebody else to do it for them. So that's [an issue].
And also, control. So if this stuff is inside me, I can't do anything about it, you know, there's a fear, something's taking over.
2. It is hard to convince patients to start an LAI.
Yeah, it's really hard to convince people to be on long-acting, but it's because you're trying to convince the people that are most challenging.
They would rather be on oral medication and have cycles of admissions and readmissions and relapses . . . it takes sometimes a long time before people can accept injections.
3. Patients will refuse LAIs.
It's just a psychological thing, we, we just expect patients to say no, so you don't even . . .
Nine out of ten are going to say no, if you give them the option, with all the information about lower amounts of medication going in, the greater safety of the long term, you can explain all of this, but nine out of ten people are going to say no.
4. Patients fear LAIs as they could hurt or be painful.
Sometimes patients, especially young patients have some fears associated with it . . . Could one of the fears be just simply the fear that something may go wrong in the injection? You know, ranging from it may hurt to how competent is the person giving the injection.
There's some people who complain of pain.
5.
Patients have strong feelings about the needle factor.
The struggle is the method, I mean, we wouldn't even be having this discussion, it's the method, it's the needle, the injection, and the dropping.
6. Patients see LAIs as a message from treatment providers that the patient cannot manage on his own or cope. Other advantages of LAIs that participants discussed were "easy"; "psychiatrist has control as patients cannot be relied on for compliance or compliance cannot be understood from their presentation"; "easy to monitor"; "easy to ensure compliance"; "better outcomes"; "patients tend to continue seeing the good effects"; and "reliability, yeah, predictability."
There was some concern expressed about the irrevocability of an injection. "Two weeks it stays in the body, and something happens, dangerous . . ." and "One of the things with injectables, they're in there and you can't stop them the next day." Other concerns raised were about the side effects of LAIs (the idea that side effects of LAIs were greater than those of oral APs was occasionally brought up); the stigmatized nature of this treatment option; and the length of time for reaching a steady state with LAIs making them less suitable for the acute phase or in inpatient units.
Prescribing Practices Around LAIs
LAIs were generally seen as a more suitable option for patients in an involuntary context of either a CTO or a forced hospitalization or a threat of a CTO; patients with a clear history of nonadherence; and seriously ill patients, with risk factors for nonadherence, for example, "if the patient is using substances." Below is a pertinent exchange from one of the focus groups: Then they stop and then they come back in and you walk up to them and say we discussed this before, sorry, this is not up for discussion, you're going on injectable.
You have to prove noncompliance first, then you think about the injections.
I think it's funny; I think we might err on the side that they're going to be compliant, which makes no logical sense given the literature.
Regarding the treatment juncture at which LAIs were presented, LAIs were almost never seen as an option that could be presented early in the course of treatment:
Yeah, I don't think I'll choose you know injectable antipsychotic as a first choice, I don't think anybody on the table will do that, it's only if they've had past failures.
Most physicians saw LAIs as a last resort after orals have been tried ("I'm aware that I don't think of injectables unless the oral is a problem, and I'm not sure why I do it that way") or as an option for the noncompliant patient after multiple relapses ("I'd say almost 100% of the time in my practice . . . patients after 2 to 3 or 4 repeat episodes is where I start LAIs"). LAIs were therefore never presented while first discussing medication options with patients:
So I would certainly say that I would not introduce or even talk about a long-acting for someone who is coming to my clinic for the first time unless I believe that there is an adherence issue, that may be because of my own bias that injectables are painful or that the therapeutic alliance will be damaged.
The only exception to this was presented by a psychiatrist working in a forensic setting. LAIs were also generally considered unsuitable during the early treatment course of psychotic disorders.
Pragmatic Barriers to Using LAIs
Another theme that emerged pertained to pragmatic barriers to the use of LAIs: "I think not all the time, but there are practical issues that even hold me back from suggesting it, a lot of the time." These included problems with storage and lack of personnel to administer injections in small towns and (or) small centres; difficulties finding trained and available nursing staff to give injections; cost considerations (even when patients were covered for the cost of the LAI, sometimes physicians perceived LAIs as expensive and as costing the Canadian health care system); concerns about arranging injections when patients went on vacation; and difficulty transferring care to general practitioners who may not be comfortable with LAIs. Below are some appropriate quotations:
I can't get anybody to give injection to my patients.
Every town needs a facility or two.
A lot of the small centres don't even touch the injectables.
You know one can say that the patient comes first, and you shouldn't think of it, but you are working in the health care, finite amount of dollars, and I do think that to a certain extent it is our responsibility to try and balance what's best for the patient with what is also available, 'cause if in fact you spend so much more of this, then you're going to get patients who get less service, so is that fair either? 
Discussion
Our qualitative study yielded insights about physicianrelated factors, such as lack of information and (or) misinformation about LAIs; limited experience with LAIs; beliefs about patients' perceptions of LAIs; personal biases against injections; and the viewing of LAIs as being appropriate for only certain types of patients. These, along with pragmatic barriers, could explain the underuse of LAIs in the treatment of psychotic disorders in Canada. Although some psychiatrist-participants had questions about the side effects and outcomes of LAIs, note that most among them discussed various advantages of LAIs. To some extent, there seems to be a discrepancy between this acknowledgement of advantages of LAIs and their limited use. This is consistent with previous surveys of physician attitudes regarding LAIs. 19, 21 There may also be a historical context surrounding current perceptions about and the low use of LAIs. Thus focus group participants spoke about "the paradigm shift in terms of our views about the LAI" that happened along with the mass switch from FGAs to SGAs that were available only in oral form until recently.
Our study suggests that LAIs may generally be presented by psychiatrists very late in the course of treatment, often after an established pattern of nonadherence and relapses, and in the coercive context of a CTO or the threat of one. This prescribing context may further perpetuate the coercive and stigmatizing image of LAIs, and such an image, in turn, may prevent physicians from presenting it as an option early on to patients. To optimize the use of LAIs, it is critical that physicians reflect on this vicious circle surrounding prescribing practices of LAIs.
Physician beliefs regarding patient perceptions about LAIs emerged as an important theme in our analysis. Examining together the findings from our patient (see Part I, Iyer et al 22 ) and physician focus groups, there were similarities between physician and patient perceptions regarding the pragmatic disadvantages of LAIs and regarding the high costs and inconveniences associated with clinic appointments and travel arrangements. While physician-participants emphasized on the pain-and-needle factor, only 2 patients with no experience with LAIs and none of the patients currently on LAIs saw this as a salient disadvantage of LAIs. Nearly all psychiatrists in our study assumed that patients would refuse LAIs or that presenting the LAI option would negatively impact the therapeutic relationship. Therefore, they saw LAIs as an option for the noncompliant patient. However, our patient focus group study and the study by Heres et al 23 suggest that a not insignificant minority of patients may consider LAIs as a suitable option for better managing their illness and reducing the risk of relapse, and for the convenience of not having to remember to take pills every day. Further, at least one patient in our study expressed that she would have liked to be presented the LAI option much earlier in the course of treatment. The findings from the physician focus groups suggest that physicians may tend to discount the evolution in attitudes regarding LAIs among patients. There was very little awareness among physicians that patients may have favourable attitudes regarding LAIs, such as seen in our patient study and in other such studies.
While the views of the patient participants in our study do not represent the entire range of patient attitudes toward LAIs, our findings suggest that, in many if not all instances, there may be a lack of correspondence between physician beliefs regarding patient perceptions and patients' own perceptions. This lack of correspondence suggests that physicians ought to effectively inquire about and listen to what patients say about LAIs in particular and other treatment in general. Such an approach would be congruent with a patientcentred, shared decision-making 24,25 approach to treatment. There may be a continuously interacting dynamic between physician and patient attitudes. [26] [27] [28] [29] Thus how physicians perceive LAIs and what they believe about their patients' negative perceptions regarding LAIs may possibly even contribute to the actual negative perceptions of patients about LAIs. Future studies are needed to systematically examine this proposition.
The results of our study suggest a need for better education and updating of skills around LAIs among psychiatrists, ideally in a context that allows examination of attitudes (for instance, via academic detailing [30] [31] [32] ). Even though the purpose of our focus groups was merely an exploration of attitudes and experiences with LAIs, interestingly, it provided to some of the physician-participants an opportunity to reflect on their own attitudes and prescribing practices:
I'd be interested to see my own biases as to why that [LAIs] is not an option in own practice.
Yeah, so what I immediately thought was well whoever would choose it? . . . But I realize that I don't even bring it up. So that's kind of my learning piece here tonight . . . You know, why don't we just put it out as options?
Concerted efforts need to be made to address pragmatic barriers so that treatment choices are less influenced by these considerations.
Our study has several limitations. We had a relatively small sample of psychiatrists (4 groups). Nonetheless, our sample included 4 Canadian provinces. The limitations of our recruitment strategy must be acknowledged. However, no attempt was made to screen or invite psychiatrists based on their views or prescribing practices about LAIs. Unfortunately, we did not collect some important demographic information from our psychiatrist-participants, such as years of experience, age, and percent of patients with psychotic disorders in their practice. Despite these limitations, our study begins to fill a crucial knowledge gap regarding physician attitudes about LAIs in Canada. It also highlights the usefulness of qualitative research methods 33, 34 in understanding prescribing practices in psychiatry.
